Why the study?
Elderly CRT non-responders were previously primarily destined for palliative care, but destination therapy with continuous-flow LVAD became available in Japan, necessitating investigation into their prognosis and feasibility based on the J-HeartMate Risk Score.
Does the J-HeartMate Risk Score (J-HMRS) stratify prognosis and assess feasibility of destination therapy in elderly CRT non-responders?
Does the J-HeartMate Risk Score (J-HMRS) stratify prognosis and assess feasibility of destination therapy in elderly CRT non-responders?
The study investigates the use of the J-HeartMate Risk Score to assess the feasibility of destination therapy with LVADs in elderly CRT non-responders in Japan.
J-HMRS use in elderly CRT non-responders is hypothesis-generating; leaves open its role in LVAD destination therapy decisions.
Background: For elderly patients with refractory heart failure (HF), destination therapy (DT) with a continuous-flow left ventricular assist device (LVAD) is a possible treatment. The aim of DT is for long-term, satisfying quality of life on LVAD support. Previously, elderly non-responders to cardiac resynchronization therapy (CRT) were primarily destined for palliative care, but DT has been available in Japan since April 30, 2021. This study investigated the prognosis of elderly CRT non-responders and assessed the feasibility of DT in these patients based on the J-HeartMate Risk Score (J-HMRS).
No takes yet. Share an insight, caveat, or question.
Yoshimura et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: